Joseph Walewicz
Directeur Général chez NEUPATH HEALTH INC.
Fortune : 46 210 $ au 30/04/2024
Profil
Joseph Walewicz is currently the Chief Executive Officer & Director at NeuPath Health, Inc. He previously worked as an Independent Director at Warnex, Inc. from 2011 to 2014.
Joseph also held the position of Executive Director of Equity Research at CIBC World Markets, Inc. from 2005 to 2008.
He served as a Director at Klinik Health Ventures Corp.
and as an Equity Research Associate of Biotechnology at Lehman Brothers, Inc. Joseph was the Vice President at Paladin Labs, Inc. from 2009 to 2011 and Vice President of Equity Research at BMO Nesbitt Burns, Inc. (US).
He worked as the Vice President & Senior Health Care Analyst at Orion Securities, Inc. from 2004 to 2005.
Joseph was the Vice President-Business & Corporate Development at Mirati Therapeutics, Inc. from 2011 to 2013 and a Healthcare Analyst at Laurentian Bank Securities, Inc. from 2014 to 2017.
He also served as the Executive VP-Business & Corporate Development at Clementia Pharmaceuticals, Inc. from 2017 to 2019.
Joseph's current job includes being the Chief Financial Officer at Fibrocor Therapeutics LP since 2021.
He holds an MBA from McGill University and an undergraduate degree from Queen's University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NEUPATH HEALTH INC.
0,67% | 07/06/2023 | 375 694 ( 0,67% ) | 46 210 $ | 30/04/2024 |
Postes actifs de Joseph Walewicz
| Sociétés | Poste | Début |
|---|---|---|
| NEUPATH HEALTH INC. | Directeur Général | 30/09/2022 |
Anciens postes connus de Joseph Walewicz
| Sociétés | Poste | Fin |
|---|---|---|
Fibrocor Therapeutics LP
 Fibrocor Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety. | Directeur Financier/CFO | 01/03/2022 |
| CLEMENTIA PHARMACEUTICALS INC | Investor Relations Contact | 01/01/2019 |
Laurentian Bank Securities, Inc.
 Laurentian Bank Securities, Inc. Investment Banks/BrokersFinance Laurentian Bank Securities is an independent broker/dealer located in Montreal. They are a subsidiary of Laurentian Bank of Canada (TOR:LB). The firm provides a full array of trading and execution services for their clients. They do not provide any internal research. | Analyst-Equity | 01/04/2017 |
| WARNEX INC. | Directeur/Membre du Conseil | 01/01/2014 |
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 01/01/2013 |
Formation de Joseph Walewicz
| McGill University | Masters Business Admin |
| Queen's University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEUPATH HEALTH INC. | Finance |
| Entreprise privées | 12 |
|---|---|
Orion Securities, Inc.
 Orion Securities, Inc. Investment Banks/BrokersFinance Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks | Finance |
CIBC World Markets, Inc.
 CIBC World Markets, Inc. Investment Banks/BrokersFinance CIBC World Markets, Inc. is a full-service Canadian brokerage and investment banking firm headquartered in Toronto, Ontario. The firm was founded in 1961 and is a subsidiary of the Canadian Imperial Bank of Commerce (TSE, NYSE: CM). CIBC World Markets provides alternative investment managers with premier prime brokerage that brings together trade execution, reporting, research and capital introduction with a view to enhancing efficiencies and profitability. | Finance |
Paladin Labs, Inc.
 Paladin Labs, Inc. Pharmaceuticals: MajorHealth Technology Paladin Labs Inc. operates as pharmaceutical company. It engages in developing, acquiring, in-licensing, marketing, and distributing innovative pharmaceutical products in Canada and internationally. The firm's products include Abstral, GlucaGen, Metadol, Plan B, Pennsaid, Seasonale, Testim, Twinject, Dexedrin, Tridural, and Trelstar. The company was founded by Jonathan Ross Goodman and Mark Beaudet on February 25, 1983 and is headquartered in Montreal, Canada. | Health Technology |
Warnex, Inc.
 Warnex, Inc. Medical SpecialtiesHealth Technology Warnex, Inc. engages as a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical sector. The company was founded on January 4, 1996 and is headquartered in Laval, Canada. | Health Technology |
Laurentian Bank Securities, Inc.
Laurentian Bank Securities, Inc. Investment Banks/BrokersFinance Laurentian Bank Securities is an independent broker/dealer located in Montreal. They are a subsidiary of Laurentian Bank of Canada (TOR:LB). The firm provides a full array of trading and execution services for their clients. They do not provide any internal research. | Finance |
| BMO Nesbitt Burns, Inc. (US) | Finance |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
Clementia Pharmaceuticals, Inc.
 Clementia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada. | Health Technology |
Klinik Health Ventures Corp.
 Klinik Health Ventures Corp. Financial ConglomeratesFinance Klinik Health Ventures Corp. operates as a capital pool company. The company was founded on April 17, 2019 and is headquartered in Toronto, Canada. | Finance |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Licensing Executives Society USA & Canada, Inc.
 Licensing Executives Society USA & Canada, Inc. Miscellaneous Commercial ServicesCommercial Services Licensing Executives Society USA & Canada, Inc. is an association that operates for intellectual property, technology, and business development professionals. The non-profit company is based in Reston, VA. The company was founded in 1965. | Commercial Services |
Fibrocor Therapeutics LP
Fibrocor Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety. | Commercial Services |
